BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 12942549)

  • 1. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
    Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
    J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between MAP kinase pathways is involved in IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell migration.
    Fu P; Liang GJ; Khot SS; Phan R; Bach LA
    J Cell Physiol; 2010 Sep; 224(3):636-43. PubMed ID: 20432455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts.
    Hilal G; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D
    Arthritis Rheum; 1999 Oct; 42(10):2112-22. PubMed ID: 10524682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.
    Minniti CP; Maggi M; Helman LJ
    Cancer Res; 1992 Apr; 52(7):1830-5. PubMed ID: 1312901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR; Church FC
    Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
    Chang MH; Kuo WW; Chen RJ; Lu MC; Tsai FJ; Kuo WH; Chen LY; Wu WJ; Huang CY; Chu CH
    J Mol Endocrinol; 2008 Aug; 41(2):65-74. PubMed ID: 18495691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.
    Chazaud B; Bonavaud S; Plonquet A; Pouchelet M; Gherardi RK; Barlovatz-Meimon G
    Exp Cell Res; 2000 Aug; 258(2):237-44. PubMed ID: 10896774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases.
    Angelloz-Nicoud P; Harel L; Binoux M
    Growth Regul; 1996 Sep; 6(3):130-6. PubMed ID: 8894645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell proliferation and migration in glioblastoma multiforme cell lines are influenced by insulin-like growth factor I in vitro.
    Schlenska-Lange A; Knüpfer H; Lange TJ; Kiess W; Knüpfer M
    Anticancer Res; 2008; 28(2A):1055-60. PubMed ID: 18507054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCG increases trophoblast migration in vitro via the insulin-like growth factor-II/mannose-6 phosphate receptor.
    Zygmunt M; McKinnon T; Herr F; Lala PK; Han VK
    Mol Hum Reprod; 2005 Apr; 11(4):261-7. PubMed ID: 15749784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
    El-Badry OM; Minniti C; Kohn EC; Houghton PJ; Daughaday WH; Helman LJ
    Cell Growth Differ; 1990 Jul; 1(7):325-31. PubMed ID: 2177632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.